The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease

Expert Rev Clin Pharmacol. 2024 May-Jun;17(5-6):415-418. doi: 10.1080/17512433.2024.2333776. Epub 2024 Mar 22.

Authors

Panagiotis I Georgianos¹, Vasilios Vaios¹, Ioannis Kontogiorgos¹, Maria Divani², Vassilios Liakopoulos¹

Affiliations

¹ 2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Hemodialysis Unit, General Hospital of Larissa, Larissa, Greece.

PMID: 38511397
DOI: 10.1080/17512433.2024.2333776

No abstract available

Keywords: CKD; Chlorthalidone; randomized controlled trials; resistant hypertension; spironolactone.

Publication types

Editorial

MeSH terms

Antihypertensive Agents* / administration & dosage
Antihypertensive Agents* / adverse effects
Antihypertensive Agents* / pharmacology
Chlorthalidone* / administration & dosage
Chlorthalidone* / pharmacology
Diuretics / administration & dosage
Diuretics / pharmacology
Drug Resistance
Evidence-Based Medicine
Humans
Hypertension* / drug therapy
Hypertension* / physiopathology
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

Chlorthalidone
Antihypertensive Agents
Diuretics